Agonists: drugs that turn the target on
Many receptors are like switches that the body's own signals flip on. A drug that binds and flips the same switch on is an agonist — it mimics the natural messenger and produces a response. If it can drive the receptor to its full maximum response, it's a full agonist: high intrinsic activity, strong efficacy. Think of it as not just unlocking the door but pushing it wide open.
A partial agonist binds and switches the receptor on too, but can only push it part way: even when every receptor is occupied, the maximum response stays below what a full agonist reaches. Its intrinsic activity is real but limited. This in-between behavior is surprisingly useful — a partial agonist gives a gentle, capped signal and can even blunt an overactive natural signal by occupying receptors a full agonist would otherwise drive hard.
Antagonists: drugs that block without acting
An antagonist is the quiet bouncer. It binds the receptor — often with high affinity — but has zero intrinsic activity: sitting in the pocket, it does nothing on its own. Its whole effect is occupancy. By filling the pocket, it keeps the natural messenger (or an agonist drug) from getting in and switching the receptor on. The result is silence where there would have been a signal.
When the antagonist competes for the same pocket as the agonist, this is competitive blockade: whoever is present in greater amount tends to win, so a higher dose of agonist can overwhelm the antagonist, and vice versa. (We'll quantify exactly this push-and-pull when we meet IC50 and Schild analysis.) Beta-blockers and antihistamines are everyday antagonists — they don't trigger the receptor, they just keep the body's own activator off it.
Inverse agonists and the full spectrum
Here's the twist that surprises most newcomers: some receptors are a little "on" even with nothing bound — they have baseline activity. A plain antagonist just freezes that baseline in place. An inverse agonist does more: it binds and actively pushes the receptor below its resting level, turning down a signal that was running on its own. It is, in effect, an agonist with negative efficacy.
Response of the receptor, low → high: inverse agonist below baseline (turns it DOWN past rest) ----------------- baseline ----------------- antagonist holds baseline (blocks others, does nothing itself) partial agonist partial rise (some effect, capped below max) full agonist maximum rise (full effect) It's one continuous scale of EFFICACY, from negative to full.